Chemoprevention for neurofibromatosis 2: just over the horizon?

by Plotkin, Scott R.
Published 2014

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis

by Blakeley, Jaishri O., Plotkin, Scott R.
Published in Neuro Oncol (2016)

INNV-20. UTILITY OF TELEHEALTH FOR SPECIALTY NEUROFIBROMATOSIS (NF) CARE

by Jordan, Justin, Seijo, Marlon, Merker, Vanessa, Bhadola, Shivkumar, Thalheimer, Raquel, Plotkin, Scott R
Published in Neuro Oncol (2018)

Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients

by Merker, Vanessa L., Esparza, Sonia, Smith, Miriam J., Stemmer-Rachamimov, Anat, Plotkin, Scott R.
Published 2012

Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study

by Terry, Anna R., Barker, Fred G., Leffert, Lisa, Bateman, Brian T., Souter, Irene, Plotkin, Scott R.
Published 2012

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schw...

by Merker, Vanessa L., Dai, Annie, Radtke, Heather B., Knight, Pamela, Jordan, Justin T., Plotkin, Scott R.
Published in BMC Health Serv Res (2018)

Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients

by Plotkin, Scott R., Halpin, Chris, McKenna, Michael J., Loeffler, Jay S., Batchelor, Tracy T., Barker, Fred G.
Published 2010

Effective Provider-Patient Communication of a Rare Disease Diagnosis: A Qualitative Study of People Diagnosed with Schwannomatosis

by Merker, Vanessa L., Plotkin, Scott R., Charns, Martin P., Meterko, Mark, Jordan, Justin T., Elwy, A. Rani
Published in Patient Educ Couns (2020)

Expression of SMARCB1 (INI1) mutations in familial schwannomatosis

by Smith, Miriam J., Walker, James A., Shen, Yiping, Stemmer-Rachamimov, Anat, Gusella, James F., Plotkin, Scott R.
Published 2012

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

by Beauchamp, Roberta L., Erdin, Serkan, Witt, Luke, Jordan, Justin T., Plotkin, Scott R., Gusella, James F., Ramesh, Vijaya
Published in J Biol Chem (2020)

Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome

by Wang, Daphne L., Smith, Kelly B., Esparza, Sonia, Leigh, Fawn A., Muzikansky, Alona, Park, Elyse R., Plotkin, Scott R.
Published 2012

Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth

by James, Marianne F., Lelke, Johanna M., MacCollin, Mia, Plotkin, Scott R., Stemmer-Rachamimov, Anat O., Ramesh, Vijaya, Gusella, James F.
Published 2007

Improvement in patient-reported hearing after treatment with bevacizumab in people with Neurofibromatosis Type 2

by Huang, Victoria, Bergner, Amanda L., Halpin, Chris, Merker, Vanessa L., Sheridan, Monica R., Widemann, Brigitte, Blakeley, Jaishri O., Plotkin, Scott R.
Published in Otol Neurotol (2018)

NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth

by James, Marianne F., Han, Sangyeul, Polizzano, Carolyn, Plotkin, Scott R., Manning, Brendan D., Stemmer-Rachamimov, Anat O., Gusella, James F., Ramesh, Vijaya
Published 2009

Achieving consensus for clinical trials: The REiNS International Collaboration

by Plotkin, Scott R., Blakeley, Jaishri O., Dombi, Eva, Fisher, Michael J., Hanemann, C. Oliver, Walsh, Karin S., Wolters, Pamela L., Widemann, Brigitte C.
Published 2013

Conclusions and future directions for the REiNS International Collaboration

by Widemann, Brigitte C., Blakeley, Jaishri O., Dombi, Eva, Fisher, Michael J., Hanemann, Clemens O., Walsh, Karin S., Wolters, Pamela L., Plotkin, Scott R.
Published 2013

Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics

by Liu, Yunpeng, Jordan, Justin T., Bredella, Miriam A., Erdin, Serkan, Walker, James A., Vangel, Mark, Harris, Gordon J., Plotkin, Scott R., Cai, Wenli
Published in Neurology (2020)

The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research

by Radtke, Heather B., Klein-Tasman, Bonita P., Merker, Vanessa L., Knight, Pamela, Ullrich, Nicole J., Jordan, Justin T., Korf, Bruce, Plotkin, Scott R.
Published in Orphanet J Rare Dis (2021)

Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors

by Wong, Hon Kit, Lahdenranta, Johanna, Kamoun, Walid S., Chan, Annie W., McClatchey, Andrea I., Plotkin, Scott R., Jain, Rakesh K., di Tomaso, Emmanuelle
Published in Cancer Res (2010)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

by Klesse, Laura J., Jordan, Justin T., Radtke, Heather B., Rosser, Tena, Schorry, Elizabeth, Ullrich, Nicole, Viskochil, David, Knight, Pamela, Plotkin, Scott R., Yohay, Kaleb
Published in Oncologist (2020)